Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Lundbeck Boosts US R&D Capability With $400m Abide Theraputics Bid

Executive Summary

Danish neuroscience company plans to acquire Abide Therapeutics for $250m upfront and up to $150m in milestones to access serine hydrolase drug discovery platform.

You may also be interested in...



Lundbeck Set For 'Transformative' Eptinezumab Launch

The Danish drugmaker's four 'strategic brands' – Brintellix, Abilify Maintena, Northera and Rexulti – are selling well. Now the focus is firmly on breaking into the anti-CGRP market with eptinezumab.

Lundbeck CEO: Alder Buy Will Boost Pipeline

Deborah Dunsire tells Scrip that buying Alder offers Lundbeck a blockbuster prevention treatment for severe migraine patients, and helps rebuild Danish group’s prospects.

Lundbeck Looks To Pipeline As Generic Competition Hits

Lundbeck highlighted R&D and the strong growth of four strategic products in the first half, as revenues were hit by generic competitors to top-selling products.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC125173

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel